id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-D-4643-0002,FDA,FDA-2024-D-4643,Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products; Guidance for Industry - Draft Guidance,Other,Guidance,2024-11-27T05:00:00Z,2024,11,2024-11-27T05:00:00Z,2025-01-28T04:59:59Z,2025-07-23T09:00:21Z,,1,0,090000648683b3d3
FDA-2024-D-4643-0001,FDA,FDA-2024-D-4643,Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2024-11-27T05:00:00Z,2024,11,2024-11-27T05:00:00Z,,2024-11-27T14:51:02Z,2024-27804,0,0,090000648683b280